IYH iShares U.S. Healthcare ETF
Company Analysis
Latest News
U.S. Probes German Drug Pricing, Threatening Tariffs Following Eli Lilly Investment Cuts
The U.S. government initiated a formal trade investigation into Germany’s proposed drug-pricing reforms under Section 301 of the Trade Act of 1974. This probe...
FDA Issues High-Risk Alert for Johnson & Johnson's Abiomed Heart Pump
The U.S. Food and Drug Administration (FDA) has issued an alert for a 'potentially high-risk' leakage issue with Abiomed's Impella heart pump introducer kits....
Merck Wins FDA Approval for CAPVAXIVE in At-Risk Children
Merck received FDA approval for an expanded indication of its CAPVAXIVE vaccine. The approval covers children and adolescents aged 2 through 17 with underlying...
uniQure Surges as FDA Eases Path for Huntington’s Gene Therapy
The FDA reversed its stance to allow uniQure to file for accelerated approval of AMT-130, a Huntington's disease gene therapy. The agency will accept...
Pfizer settles 5,000 lawsuits, resolving Depo-Provera brain tumor claims
Pfizer reached a settlement in principle to resolve more than 5,000 lawsuits involving its Depo-Provera birth control shot. A Monday court filing confirmed the...
Johnson & Johnson invests $1B in ACUVUE, strengthening domestic supply chains
Johnson & Johnson will invest over $1 billion to expand its Vision operations in Jacksonville, Florida. The capital will scale domestic manufacturing,...
Legend Biotech Reports 100% Response Rate for In Vivo CAR-T Therapy
Legend Biotech (NASDAQ: LEGN) released clinical proof-of-concept data for LB2501, an investigational in vivo CAR-T cell therapy. The company presented the...
Johnson & Johnson Myeloma Combo Slashes Progression Risk by 72%
Johnson & Johnson announced Phase 3 MonumenTAL-3 study results for its TALVEY (talquetamab-tgvs) and DARZALEX FASPRO combination. The trial evaluated the...
J&J Reports Positive IMAAVY Data, Eyeing First-Ever Rare Blood Disorder Treatment
Johnson & Johnson reported positive initial results from its Phase II/III ENERGY trial for IMAAVY (nipocalimab-aahu). The investigational treatment targets...
Takeda’s zasocitinib beats BMS’s Sotyktu, showing 2.5x higher skin clearance
Takeda reported positive topline results from the LATITUDE Atlas Phase 3 study. The oral TYK2 inhibitor zasocitinib proved statistically superior to Bristol...
Eli Lilly widens obesity lead, sending rival Novo Nordisk shares lower
Eli Lilly presented detailed trial data for its experimental obesity drug, retatrutide, at the American Diabetes Association (ADA) conference. The data...
GSK acquires Nuvalent for $10.6B, targeting blockbuster lung cancer drugs
GSK signed a definitive agreement to acquire Nuvalent for $10.6 billion. The transaction secures a portfolio of next-generation precision cancer therapies and...
Eli Lilly surges, fueled by 30% weight loss for retatrutide
Eli Lilly released late-stage clinical trial data for its next-generation weight-loss drug, retatrutide. The drug led to a 30.3% average reduction in body...
Novo Nordisk Oral Wegovy Hits 3M Prescriptions, Expanding Obesity Treatment Market
Novo Nordisk’s oral Wegovy surpassed three million U.S. prescriptions since its January 2026 launch. This volume represents one of the most successful...
Roche Challenges Obesity Leaders, Reporting 22.7% Weight Loss in Trial
Roche reported that patients using its experimental drug enicepatide lost 22.7% of their body weight. This result occurred during a 48-week mid-stage trial....
CVS Reverses Course to Cover Eli Lilly’s Zepbound, Challenging Novo Nordisk
CVS Caremark will begin covering Eli Lilly’s weight-loss medication, Zepbound, starting October 1, 2026. This decision marks a significant reversal for the...
🟢 iShares U.S. Healthcare ETF is trading 3.1% up today as investors rotate into defensive healthcare
iShares U.S. Healthcare ETF is trading 3.1% up as capital rotates out of volatile tech and AI-linked growth stocks into more defensive sectors like...
Johnson & Johnson’s ERLEADA Cuts Cancer Risk 20%, Setting New Treatment Standard
Johnson & Johnson released final Phase 3 PROTEUS study results for its prostate cancer drug, ERLEADA (apalutamide). The study focused on patients with...
J&J ERLEADA Cuts Prostate Cancer Risk by 20%, Shifting Treatment Standards
Johnson & Johnson announced final Phase 3 PROTEUS study results for ERLEADA (apalutamide). The drug significantly improved outcomes for patients with high-risk...
Johnson & Johnson’s Erleada cuts prostate cancer metastasis risk by 20%
Johnson & Johnson reported that ERLEADA (apalutamide) combined with hormone therapy reduced the risk of metastasis or death by 20% in high-risk prostate cancer...